|
|
|
Volumn 24, Issue 2 SUPPL. 7, 1997, Pages
|
|
Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: An estimate using the population health model lung cancer module
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
GEMCITABINE;
ANTINEOPLASTIC ANTIMETABOLITE;
DEOXYCYTIDINE;
DRUG DERIVATIVE;
RIBONUCLEOTIDE REDUCTASE;
ANTINEOPLASTIC ACTIVITY;
CANADA;
CANCER STAGING;
CANCER SURVIVAL;
CONFERENCE PAPER;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
DRUG EFFICACY;
HUMAN;
LUNG NON SMALL CELL CANCER;
MAJOR CLINICAL STUDY;
PRIORITY JOURNAL;
SURVIVAL TIME;
ARTICLE;
COST BENEFIT ANALYSIS;
DRUG ANTAGONISM;
ECONOMICS;
HEALTH CARE COST;
HEALTH CARE PLANNING;
LUNG TUMOR;
MORTALITY;
STATISTICAL MODEL;
SURVIVAL RATE;
ANTIMETABOLITES, ANTINEOPLASTIC;
CANADA;
CARCINOMA, NON-SMALL-CELL LUNG;
COST-BENEFIT ANALYSIS;
DEOXYCYTIDINE;
HEALTH CARE COSTS;
HEALTH RESOURCES;
HUMANS;
LUNG NEOPLASMS;
MODELS, ECONOMIC;
NEOPLASM STAGING;
RIBONUCLEOTIDE REDUCTASES;
SURVIVAL RATE;
|
|
EID: 0030969980
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (25)
|
|
References (26)
|
